BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koshy S, Wu D, Hu X, Tajhya RB, Huq R, Khan FS, Pennington MW, Wulff H, Yotnda P, Beeton C. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One 2013;8:e76740. [PMID: 24146918 DOI: 10.1371/journal.pone.0076740] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Kaschek L, Zöphel S, Knörck A, Hoth M. A calcium optimum for cytotoxic T lymphocyte and natural killer cell cytotoxicity. Semin Cell Dev Biol 2021;115:10-8. [PMID: 33358089 DOI: 10.1016/j.semcdb.2020.12.002] [Reference Citation Analysis]
2 Rabjerg M, Oliván-Viguera A, Hansen LK, Jensen L, Sevelsted-Møller L, Walter S, Jensen BL, Marcussen N, Köhler R. High expression of KCa3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival. PLoS One 2015;10:e0122992. [PMID: 25848765 DOI: 10.1371/journal.pone.0122992] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
3 Tanner MR, Hu X, Huq R, Tajhya RB, Sun L, Khan FS, Laragione T, Horrigan FT, Gulko PS, Beeton C. KCa1.1 inhibition attenuates fibroblast-like synoviocyte invasiveness and ameliorates disease in rat models of rheumatoid arthritis. Arthritis Rheumatol 2015;67:96-106. [PMID: 25252152 DOI: 10.1002/art.38883] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
4 Panyi G, Beeton C, Felipe A. Ion channels and anti-cancer immunity. Philos Trans R Soc Lond B Biol Sci 2014;369:20130106. [PMID: 24493754 DOI: 10.1098/rstb.2013.0106] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
5 Yuki K, Eckenhoff RG. Mechanisms of the Immunological Effects of Volatile Anesthetics: A Review. Anesth Analg 2016;123:326-35. [PMID: 27308954 DOI: 10.1213/ANE.0000000000001403] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 8.4] [Reference Citation Analysis]
6 Steudel FA, Mohr CJ, Stegen B, Nguyen HY, Barnert A, Steinle M, Beer-Hammer S, Koch P, Lo WY, Schroth W, Hoppe R, Brauch H, Ruth P, Huber SM, Lukowski R. SK4 channels modulate Ca2+ signalling and cell cycle progression in murine breast cancer. Mol Oncol 2017;11:1172-88. [PMID: 28557306 DOI: 10.1002/1878-0261.12087] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
7 Leanza L, Managò A, Zoratti M, Gulbins E, Szabo I. Pharmacological targeting of ion channels for cancer therapy: In vivo evidences. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2016;1863:1385-97. [DOI: 10.1016/j.bbamcr.2015.11.032] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 9.0] [Reference Citation Analysis]
8 Pierri CL, Bossis F, Punzi G, De Grassi A, Cetrone M, Parisi G, Tricarico D. Molecular modeling of antibodies for the treatment of TNFα-related immunological diseases. Pharmacol Res Perspect. 2016;4:e00197. [PMID: 26977294 DOI: 10.1002/prp2.197] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
9 Norton RS, Chandy KG. Venom-derived peptide inhibitors of voltage-gated potassium channels. Neuropharmacology 2017;127:124-38. [PMID: 28689025 DOI: 10.1016/j.neuropharm.2017.07.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
10 Wu L, Lian W, Zhao L. Calcium signaling in cancer progression and therapy. FEBS J 2021. [PMID: 34288422 DOI: 10.1111/febs.16133] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Ramírez A, García-Quiroz J, Aguilar-Eslava L, Sánchez-Pérez Y, Camacho J. Novel Therapeutic Approaches of Ion Channels and Transporters in Cancer. Rev Physiol Biochem Pharmacol 2020. [PMID: 32715321 DOI: 10.1007/112_2020_28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Geng J, Wang Y, Zhang L, Wang R, Li C, Sheng W, Li Z, Jiang M. The cajanine derivative LJ101019C regulates the proliferation and enhances the activity of NK cells via Kv1.3 channel-driven activation of the AKT/mTOR pathway. Phytomedicine 2020;66:153113. [PMID: 31790901 DOI: 10.1016/j.phymed.2019.153113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
13 Pérez-García MT, Cidad P, López-López JR. The secret life of ion channels: Kv1.3 potassium channels and proliferation. Am J Physiol Cell Physiol 2018;314:C27-42. [PMID: 28931540 DOI: 10.1152/ajpcell.00136.2017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
14 Marshall HT, Djamgoz MBA. Immuno-Oncology: Emerging Targets and Combination Therapies. Front Oncol. 2018;8:315. [PMID: 30191140 DOI: 10.3389/fonc.2018.00315] [Cited by in Crossref: 134] [Cited by in F6Publishing: 125] [Article Influence: 33.5] [Reference Citation Analysis]
15 Liu H, Song M, Fang F, Gao X, Zhang Z, Wang S. Prediction of chemotherapeutic efficacy using the ratio of neutrophils to lymphocytes in patients with unresectable or recurrent gastric cancer. Oncol Lett 2015;10:2244-8. [PMID: 26622827 DOI: 10.3892/ol.2015.3575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Bose T, Cieślar-Pobuda A, Wiechec E. Role of ion channels in regulating Ca²⁺ homeostasis during the interplay between immune and cancer cells. Cell Death Dis 2015;6:e1648. [PMID: 25695601 DOI: 10.1038/cddis.2015.23] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 7.4] [Reference Citation Analysis]
17 Tanner MR, Beeton C. Differences in ion channel phenotype and function between humans and animal models. Front Biosci (Landmark Ed) 2018;23:43-64. [PMID: 28930537 DOI: 10.2741/4581] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
18 Schulte-Mecklenbeck A, Bittner S, Ehling P, Döring F, Wischmeyer E, Breuer J, Herrmann AM, Wiendl H, Meuth SG, Gross CC. The two-pore domain K2 P channel TASK2 drives human NK-cell proliferation and cytolytic function. Eur J Immunol 2015;45:2602-14. [PMID: 26140335 DOI: 10.1002/eji.201445208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
19 Beeton C. KCa1.1 channels as therapeutic targets for rheumatoid arthritis. Expert Opin Ther Targets 2017;21:1077-81. [PMID: 29076378 DOI: 10.1080/14728222.2017.1398234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 RamaKrishnan AM, Sankaranarayanan K. Understanding autoimmunity: The ion channel perspective. Autoimmun Rev 2016;15:585-620. [PMID: 26854401 DOI: 10.1016/j.autrev.2016.02.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
21 Tanner MR, Pennington MW, Chauhan SS, Laragione T, Gulko PS, Beeton C. KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis. Arthritis Res Ther 2019;21:6. [PMID: 30612588 DOI: 10.1186/s13075-018-1783-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
22 Chang SC, Huq R, Chhabra S, Beeton C, Pennington MW, Smith BJ, Norton RS. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3. FEBS J 2015;282:2247-59. [PMID: 25864722 DOI: 10.1111/febs.13294] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
23 Koshy S, Huq R, Tanner MR, Atik MA, Porter PC, Khan FS, Pennington MW, Hanania NA, Corry DB, Beeton C. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem 2014;289:12623-32. [PMID: 24644290 DOI: 10.1074/jbc.M113.517037] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
24 Checchetto V, Leanza L, De Stefani D, Rizzuto R, Gulbins E, Szabo I. Mitochondrial K+ channels and their implications for disease mechanisms. Pharmacol Ther 2021;227:107874. [PMID: 33930454 DOI: 10.1016/j.pharmthera.2021.107874] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Hofschröer V, Najder K, Rugi M, Bouazzi R, Cozzolino M, Arcangeli A, Panyi G, Schwab A. Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy. Front Pharmacol 2020;11:586599. [PMID: 33841132 DOI: 10.3389/fphar.2020.586599] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Kulemzin S, Evsyukov I, Belovezhets T, Taranin A, Gorchakov A. Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies. J Pers Med 2021;11:1182. [PMID: 34834534 DOI: 10.3390/jpm11111182] [Reference Citation Analysis]
27 Zhang L, Bing S, Dong M, Lu X, Xiong Y. Targeting ion channels for the treatment of lung cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188629. [PMID: 34610420 DOI: 10.1016/j.bbcan.2021.188629] [Reference Citation Analysis]
28 Foo NP, Liu YF, Wu PC, Hsing CH, Huang BM, So EC. Midazolam's Effects on Delayed-Rectifier K+ Current and Intermediate-Conductance Ca2+-Activated K+ Channel in Jurkat T-lymphocytes. Int J Mol Sci 2021;22:7198. [PMID: 34281255 DOI: 10.3390/ijms22137198] [Reference Citation Analysis]
29 Tajhya RB, Hu X, Tanner MR, Huq R, Kongchan N, Neilson JR, Rodney GG, Horrigan FT, Timchenko LT, Beeton C. Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts. Cell Death Dis 2016;7:e2426. [PMID: 27763639 DOI: 10.1038/cddis.2016.324] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
30 Ganser K, Klumpp L, Bischof H, Lukowski R, Eckert F, Huber SM. Potassium Channels in Cancer. Handb Exp Pharmacol 2021. [PMID: 33864122 DOI: 10.1007/164_2021_465] [Reference Citation Analysis]
31 Mohr CJ, Steudel FA, Gross D, Ruth P, Lo WY, Hoppe R, Schroth W, Brauch H, Huber SM, Lukowski R. Cancer-Associated Intermediate Conductance Ca2+-Activated K⁺ Channel KCa3.1. Cancers (Basel) 2019;11:E109. [PMID: 30658505 DOI: 10.3390/cancers11010109] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
32 Rashid MH, Huq R, Tanner MR, Chhabra S, Khoo KK, Estrada R, Dhawan V, Chauhan S, Pennington MW, Beeton C, Kuyucak S, Norton RS. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Sci Rep 2014;4:4509. [PMID: 24676092 DOI: 10.1038/srep04509] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]